Medication-Overuse Headache.

Journal

Continuum (Minneapolis, Minn.)

ISSN: 1538-6899

Titre abrégé: Continuum (Minneap Minn)

Pays: United States

ID NLM: 9509333

Informations de publication

Date de publication:
01 Apr 2024

Historique:

medline: 3 4 2024

pubmed: 3 4 2024

entrez: 3 4 2024

Statut: ppublish

Résumé

Medication-overuse headache (MOH) has been described for almost 100 years and is characterized as a daily or near-daily headache that usually presents in patients with preexisting primary headache disorders who are overusing one or more acute or symptomatic headache medications. This article reviews the diagnosis and management of patients with MOH. The International Classification of Headache Disorders criteria for MOH have changed over time. The worldwide prevalence appears to be between 1% and 2%. Together, headache disorders, including MOH, are currently ranked as the second leading cause of years lived with disability in the Global Burden of Disease world health survey. Significant neurophysiologic changes are seen in the brains of patients with MOH, including functional alterations in central pain processing and modulating systems and central sensitization. Research supports updates to the principles of management, including weaning off the overused medication, preventive therapy, biobehavioral therapy, and patient education. MOH is a fairly common and treatable secondary headache disorder that produces significant disability and a substantial reduction in quality of life. The costs related to lost income and disability are substantial. MOH is intimately related to chronic migraine, which continues to be underrecognized and undertreated. Treatment focuses on both the institution of effective preventive migraine therapy and the reduction or removal of the overused medications. Educational efforts directed toward both providers and patients have been shown to be effective in reducing the effect of MOH.

Identifiants

DOI: 10.1212/CON.0000000000001403 PMID: 38568489

pubmed: 38568489

doi: 10.1212/CON.0000000000001403

pii: 00132979-202404000-00008

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

379-390

Informations de copyright

Références

Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia Int J Headache 2018;38(1):1–211. doi:10.1177/0333102417738202

doi: 10.1177/0333102417738202

Boes CJ, Capobianco DJ. Chronic migraine and medication-overuse headache through the ages. Cephalalgia Int J Headache 2005;25(5):378–390. doi:10.1111/j.1468-2982.2005.00868.x

doi: 10.1111/j.1468-2982.2005.00868.x

Isler H. A hidden dimension in headache work: applied history of medicine. Headache 1986;26(1):27–29. doi:10.1111/j.1526-4610.1986.hed2601027.x

doi: 10.1111/j.1526-4610.1986.hed2601027.x

Rapoport AM. Analgesic rebound headache. Headache 1988;28(10):662–665. doi:10.1111/j.1526-4610.1988.hed2810662.x

doi: 10.1111/j.1526-4610.1988.hed2810662.x

Saper JR, Jones JM. Ergotamine tartrate dependency: features and possible mechanisms. Clin Neuropharmacol 1986;9(3):244–256. doi:10.1097/00002826-198606000-00003

doi: 10.1097/00002826-198606000-00003

Dodick D, Freitag F. Evidence-based understanding of medication-overuse headache: clinical implications. Headache 2006;46 Suppl 4:S202–211. doi:10.1111/j.1526-4610.2006.00604.x

doi: 10.1111/j.1526-4610.2006.00604.x

Tepper SJ. Debate: analgesic overuse is a cause, not consequence, of chronic daily headache. Analgesic overuse is a cause of chronic daily headache. Headache 2002;42(6):543–547. doi:10.1046/j.1526-4610.2002.02133_1.x

doi: 10.1046/j.1526-4610.2002.02133_1.x

Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain 2011;12(6):593–601. doi:10.1007/s10194-011-0388-3

doi: 10.1007/s10194-011-0388-3

Siberstein SD, Lipton RB, Solomon S, Mathew NT. Classification of daily and near-daily headaches: proposed revisions to the IHS criteria. Headache 1994;34(1):1–7. doi:10.1111/j.1526-4610.1994.hed3401001.x

doi: 10.1111/j.1526-4610.1994.hed3401001.x

Bigal ME, Tepper SJ, Sheftell FD, Rapoport AM, Lipton RB. Chronic daily headache: correlation between the 2004 and the 1988 International Headache Society diagnostic criteria. Headache 2004;44(7):684–691. doi:10.1111/j.1526-4610.2004.04128.x

doi: 10.1111/j.1526-4610.2004.04128.x

Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia Int J Headache 2004;24 Suppl 1:9–160. doi:10.1111/j.1468-2982.2003.00824.x

doi: 10.1111/j.1468-2982.2003.00824.x

Schembri E, Barrow M, McKenzie C, Dawson A. The evolving classifications and epidemiological challenges surrounding chronic migraine and medication overuse headache: a review. Korean J Pain 2022;35(1):4–13. doi:10.3344/kjp.2022.35.1.4

doi: 10.3344/kjp.2022.35.1.4

Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 2012;52(10):1456–1470. doi:10.1111/j.1526-4610.2012.02223.x

doi: 10.1111/j.1526-4610.2012.02223.x

Westergaard ML, Hansen EH, Glümer C, Olesen J, Jensen RH. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia Int J Headache 2014;34(6):409–425. doi:10.1177/0333102413512033

doi: 10.1177/0333102413512033

Jonsson P, Hedenrud T, Linde M. Epidemiology of medication overuse headache in the general Swedish population. Cephalalgia Int J Headache 2011;31(9):1015–1022. doi:10.1177/0333102411410082

doi: 10.1177/0333102411410082

Loder EW, Scher AI. Medication overuse headache: the trouble with prevalence estimates. Cephalalgia Int J Headache 2020;40(1):3–5. doi:10.1177/0333102419876907

doi: 10.1177/0333102419876907

GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 2017;16(11):877–897. doi:10.1016/S1474-4422(17)30299-5

doi: 10.1016/S1474-4422(17)30299-5

GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17(11):954–976. doi:10.1016/S1474-4422(18)30322-3

doi: 10.1016/S1474-4422(18)30322-3

Romozzi M, Di Tella S, Rollo E, et al. Theory of Mind in migraine and medication-overuse headache: a cross-sectional study. Front Neurol 2022;13:968111. doi:10.3389/fneur.2022.968111

doi: 10.3389/fneur.2022.968111

Oh SY, Kang JJ, Park HK, et al. Clinical characteristics of medication-overuse headache according to the class of acute medication: a cross-sectional multicenter study. Headache 2022;62(7):890–902. doi:10.1111/head.14363

doi: 10.1111/head.14363

Tepper SJ. Medication-overuse headache. Continuum (Minneap Minn) 2012;18(4):807–822. doi:10.1212/01.CON.0000418644.32032.7b

doi: 10.1212/01.CON.0000418644.32032.7b

Saper JR, Hamel RL, Lake AE. Medication overuse headache (MOH) is a biobehavioural disorder. Cephalalgia Int J Headache 2005;25(7):545–546. doi:10.1111/j.1468-2982.2005.00879.x

doi: 10.1111/j.1468-2982.2005.00879.x

Srikiatkhachorn A, le Grand SM, Supornsilpchai W, Storer RJ. Pathophysiology of medication overuse headache–an update. Headache 2014;54(1):204–210. doi:10.1111/head.12224

doi: 10.1111/head.12224

Diener HC, Dodick D, Evers S, et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol 2019;18(9):891–902. doi:10.1016/S1474-4422(19)30146-2

doi: 10.1016/S1474-4422(19)30146-2

Ferraro S, Grazzi L, Muffatti R, et al. In medication-overuse headache, fMRI shows long-lasting dysfunction in midbrain areas. Headache 2012;52(10):1520–1534. doi:10.1111/j.1526-4610.2012.02276.x

doi: 10.1111/j.1526-4610.2012.02276.x

Riederer F, Marti M, Luechinger R, et al. Grey matter changes associated with medication-overuse headache: correlations with disease related disability and anxiety. World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry 2012;13(7):517–525. doi:10.3109/15622975.2012.665175

doi: 10.3109/15622975.2012.665175

Schwedt TJ, Chong CD. Medication overuse headache: pathophysiological insights from structural and functional brain mri research. Headache 2017;57(7):1173–1178. doi:10.1111/head.13037

doi: 10.1111/head.13037

Mehnert J, Hebestreit J, May A. Cortical and subcortical alterations in medication overuse headache. Front Neurol 2018;9:499. doi:10.3389/fneur.2018.00499

doi: 10.3389/fneur.2018.00499

Lai TH, Chou KH, Fuh JL, et al. Gray matter changes related to medication overuse in patients with chronic migraine. Cephalalgia Int J Headache 2016;36(14):1324–1333. doi:10.1177/0333102416630593

doi: 10.1177/0333102416630593

Cargnin S, Viana M, Sances G, Tassorelli C, Terrazzino S. A systematic review and critical appraisal of gene polymorphism association studies in medication-overuse headache. Cephalalgia Int J Headache 2018;38(7):1361–1373. doi:10.1177/0333102417728244

doi: 10.1177/0333102417728244

Torta DM, Costa T, Luda E, et al. Nucleus accumbens functional connectivity discriminates medication-overuse headache. NeuroImage Clin 2016;11:686–693. doi:10.1016/j.nicl.2016.05.007

doi: 10.1016/j.nicl.2016.05.007

Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia Int J Headache 2006;26(10):1192–1198. doi:10.1111/j.1468-2982.2006.01190.x

doi: 10.1111/j.1468-2982.2006.01190.x

Schwedt TJ, Hentz JG, Sahai-Srivastava S, et al. Patient-centered treatment of chronic migraine with medication overuse: a prospective, randomized, pragmatic clinical trial. Neurology 2022;98(14):e1409–e1421. doi:10.1212/WNL.0000000000200117

doi: 10.1212/WNL.0000000000200117

Scher AI, Rizzoli PB, Loder EW. Medication overuse headache: an entrenched idea in need of scrutiny. Neurology 2017;89(12):1296–1304. doi:10.1212/WNL.0000000000004371

doi: 10.1212/WNL.0000000000004371

Diener HC, Kropp P, Dresler T, et al. Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline. Neurol Res Pract 2022;4(1):37. doi:10.1186/s42466-022-00200-0

doi: 10.1186/s42466-022-00200-0

Vandenbussche N, Laterza D, Lisicki M, et al. Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain 2018;19(1):50. doi:10.1186/s10194-018-0875-x

doi: 10.1186/s10194-018-0875-x

Zed PJ, Loewen PS, Robinson G. Medication-induced headache: overview and systematic review of therapeutic approaches. Ann Pharmacother 1999;33(1):61–72. doi:10.1345/aph.18184

doi: 10.1345/aph.18184

Chiang CC, Schwedt TJ, Wang SJ, Dodick DW. Treatment of medication-overuse headache: a systematic review. Cephalalgia Int J Headache 2016;36(4):371–386. doi:10.1177/0333102415593088

doi: 10.1177/0333102415593088

Diener HC, Dodick DW, Goadsby PJ, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia Int J Headache 2009;29(10):1021–1027. doi:10.1111/j.1468-2982.2009.01859.x

doi: 10.1111/j.1468-2982.2009.01859.x

Silberstein SD, Blumenfeld AM, Cady RK, et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 2013;331(1-2):48–56. doi:10.1016/j.jns.2013.05.003

doi: 10.1016/j.jns.2013.05.003

Pijpers JA, Kies DA, Louter MA, et al. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial. Brain J Neurol 2019;142(5):1203–1214. doi:10.1093/brain/awz052

doi: 10.1093/brain/awz052

Grazzi L, Raggi A, Guastafierro E, et al. A preliminary analysis on the feasibility and short-term efficacy of a phase-III RCT on mindfulness added to treatment as usual for patients with chronic migraine and medication overuse headache. Int J Environ Res Public Health 2022;19(21):14116. doi:10.3390/ijerph192114116

doi: 10.3390/ijerph192114116

Pijpers JA, Kies DA, van Zwet EW, Rosendaal FR, Terwindt GM. Behavioural intervention in medication overuse headache: a concealed double-blind randomized controlled trial. Eur J Neurol 2022;29(5):1496–1504. doi:10.1111/ene.15256

doi: 10.1111/ene.15256

Ashina S, Terwindt GM, Steiner TJ, et al. Medication overuse headache. Nat Rev Dis Primer 2023;9(1):5. doi:10.1038/s41572-022-00415-0

doi: 10.1038/s41572-022-00415-0

Carlsen LN, Munksgaard SB, Nielsen M, et al. Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial. JAMA Neurol 2020;77(9):1069–1078. doi:10.1001/jamaneurol.2020.1179

doi: 10.1001/jamaneurol.2020.1179

Lake AE. Screening and behavioral management: medication overuse headache–the complex case. Headache 2008;48(1):26–31. doi:10.1111/j.1526-4610.2007.00971.x

doi: 10.1111/j.1526-4610.2007.00971.x

Koumprentziotis IA, Mitsikostas DD. Therapies targeting CGRP signaling for medication overuse headache. Curr Opin Neurol 2022;35(3):353–359. doi:10.1097/WCO.0000000000001061

doi: 10.1097/WCO.0000000000001061

Cho S, Kim BK. Update of gepants in the treatment of chronic migraine. Curr Pain Headache Rep 2023;27(10):561–569. doi:10.1007/s11916-023-01167-6

doi: 10.1007/s11916-023-01167-6

Lo Castro F, Guerzoni S, Pellesi L. Safety and risk of medication overuse headache in lasmiditan and second-generation gepants: a rapid review. Drug Healthc Patient Saf 2021;13:233–240. doi:10.2147/DHPS.S304373

doi: 10.2147/DHPS.S304373

Schwedt TJ, Robert T, Dodick DW. Treatment of chronic migraine with medication overuse: a perspective. Headache 2022;62(5):642–644. doi:10.1111/head.14314

doi: 10.1111/head.14314